(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.03%) $78.14
(5.55%) $2.15
(-0.03%) $2 309.00
(-0.26%) $26.76
(0.22%) $964.75
(-0.33%) $0.929
(-1.11%) $10.87
(-0.12%) $0.797
(0.39%) $91.49
0.44% HKD 18.12
Live Chart Being Loaded With Signals
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally...
Stats | |
---|---|
Объем за сегодня | 977 288 |
Средний объем | 4.41M |
Рыночная капитализация | 11.31B |
EPS | HKD0 ( 2023-08-17 ) |
Last Dividend | HKD0.390 ( 2023-06-02 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 9.74 |
ATR14 | HKD0.00800 (0.04%) |
Объем Корреляция
SciClone Pharmaceuticals, Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
SciClone Pharmaceuticals, Корреляция - Валюта/Сырье
SciClone Pharmaceuticals, Финансовые показатели
Annual | 2023 |
Выручка: | HKD3.16B |
Валовая прибыль: | HKD2.36B (74.67 %) |
EPS: | HKD1.830 |
FY | 2023 |
Выручка: | HKD3.16B |
Валовая прибыль: | HKD2.36B (74.67 %) |
EPS: | HKD1.830 |
FY | 2022 |
Выручка: | HKD2.75B |
Валовая прибыль: | HKD2.07B (75.30 %) |
EPS: | HKD1.270 |
FY | 2021 |
Выручка: | HKD2.52B |
Валовая прибыль: | HKD1.93B (76.75 %) |
EPS: | HKD1.420 |
Financial Reports:
No articles found.
SciClone Pharmaceuticals, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.390 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.350 | 2022-05-27 |
Last Dividend | HKD0.390 | 2023-06-02 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | HKD0.740 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.31 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.58 | |
Div. Directional Score | 9.28 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3658.HK | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
1606.HK | Ex Dividend Junior | 2023-06-30 | Annually | 0 | 0.00% | |
0662.HK | Ex Dividend Knight | 2023-09-19 | Semi-Annually | 0 | 0.00% | |
9989.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
2193.HK | Ex Dividend Junior | 2023-09-06 | Sporadic | 0 | 0.00% | |
1198.HK | No Dividend Player | 2023-07-21 | Sporadic | 0 | 0.00% | |
0267.HK | Ex Dividend Junior | 2023-09-22 | Semi-Annually | 0 | 0.00% | |
3939.HK | Ex Dividend Knight | 2023-06-07 | Annually | 0 | 0.00% | |
1772.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
0811.HK | Ex Dividend Knight | 2023-05-22 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.356 | 1.500 | 2.89 | 4.33 | [0 - 0.5] |
returnOnAssetsTTM | 0.280 | 1.200 | 0.651 | 0.782 | [0 - 0.3] |
returnOnEquityTTM | 0.369 | 1.500 | 7.01 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.192 | -1.000 | 8.08 | -8.08 | [0 - 1] |
currentRatioTTM | 4.94 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.43 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.59 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00821 | -1.500 | 9.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 35.54 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.894 | 2.00 | 9.70 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.893 | 2.00 | 9.55 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0101 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.747 | 1.000 | 0.889 | 0.889 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.382 | 1.000 | 4.36 | 4.36 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 17.66 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.789 | 0.800 | 8.07 | 6.46 | [0.5 - 2] |
Total Score | 11.99 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 9.68 | 1.000 | 9.12 | 0 | [1 - 100] |
returnOnEquityTTM | 0.369 | 2.50 | 8.08 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.893 | 2.00 | 9.70 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.33 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.894 | 2.00 | 9.70 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.192 | 1.500 | 8.08 | -8.08 | [0 - 1] |
pegRatioTTM | 0.374 | 1.500 | -0.838 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.184 | 1.000 | 7.91 | 0 | [0.1 - 0.5] |
Total Score | 6.58 |
SciClone Pharmaceuticals,
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome. The company's pipeline products comprise Vibativ, a bactericidal, once-daily, injectable lipoglycopeptide antibiotic for the treatment of adult patients with hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/ leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic which treats solid tumors; PEN-866, a HSP90-binding miniature drug conjugate; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа